This site is intended for healthcare professionals only.
This site is intended for healthcare professionals only.
This enduring discussion- and case-based webinar explores the latest in NTRK fusion-positive non-small cell lung cancer (NSCLC).
Learn how to:
The videos offer subtitles in English, which can be enabled using the subtitle 
icon in the player.
Title: NTRK fusion-positive NSCLC: perspectives from pathology, oncology, and beyond
Jointly provided by Postgraduate Institute for Medicine and Springer Health+ IME
Release date: December 2, 2025
Expiration date: December 2, 2026
Estimated time: 75 minutes
This enduring webinar is aimed at oncologists, pathologists, pulmonologists, nurses and nurse practitioners, and all other members of the multidisciplinary team managing NSCLC patients.
After taking part in this program, learners will be able to:
Justin Gainor, MD (Program Director)
Assistant Professor of Medicine, Harvard Medical School
Director, Center for Thoracic Cancers, Massachusetts General Hospital
Director, Targeted Immunotherapy, Henri and Belinda Termeer Center for Targeted Therapies
Luis Paz-Ares, MD, PhD
Chair of the Medical Oncology Department at the Hospital Universitario 12 de Octubre
Associate Professor, Universidad Complutense de Madrid
Head, Lung Cancer Unit, Spanish National Cancer Research Center (CNIO)
Lynette M. Sholl, MD
Pathologist, Brigham and Women’s Hospital
Professor of Pathology, Harvard Medical School
Stevan Bradford
Patient, USA
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified financial relationships are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
Justin Gainor, MD (Program Director)
Luis Paz-Ares, MD, PhD
Lynette M. Sholl, MD
Stevan Bradford
The PIM planners and others have nothing to disclose. The Springer Health+ IME planners and others have nothing to disclose.
All relevant financial relationships have been mitigated.
The NTRK fusion-positive NSCLC: perspectives from pathology, oncology and beyond, London, UK, United Kingdom 11/11/2025 – 11/11/2025, has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 1.0 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.
Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found at https://edhub.ama-assn.org/pages/applications.
Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Springer Health+ IME. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The Postgraduate Institute for Medicine designates this activity for a maximum of 1.25 AMA PRA Category 1 Credits™.
Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
This program is aligned with Springer Medicine – an English-language, medical education platform provided by the Springer Nature Group. Springer Medicine supports doctors in their ongoing quest for optimal patient care, and delivers the latest evidence on new therapies, practice guidelines and news in easily digestible formats to keep healthcare professionals effortlessly up to date.
